Pooled Results of Two Randomized Phase 3 Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
mediaposted on 2021-02-03, 20:35 authored by Lawrence F. Eichenfield, Elaine Siegfried, Pearl Kwong, Mark McBride, Jayson Rieger, David Glover, Cynthia Willson, Matthew Davidson, Patrick Burnett, Melissa Olivadoti
The above video abstract represents the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.